Anomer Bio

Founded in 2024, Anomer Bio is dedicated to pioneering innovations in biotechnology, particularly in the realm of synthetic sugars.Glyconix specializes in the development of synthetic monosaccharides designed to modify immune responses by altering how sugars interact with proteins and cells. The core product offerings leverage machine learning approaches to model cellular processing of sugars, enabling the creation of synthetic sugars that target previously unmodifiable glycan structures. These innovations aim to address critical challenges in immunology, potentially leading to therapeutic applications in autoimmune diseases, cancer treatment, and other immune-related conditions.Glyconix generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research entities, facilitating the adoption of their synthetic sugar products in drug development processes. Transactions are structured around collaborative agreements, which may include upfront payments, milestone payments, and royalties based on the success of the developed therapies. Their flagship products, designed for specific immunological applications, are integrated into the clients' drug development pipelines, which allows for tailored pricing models specific to each partnership. The company aims to expand its market presence in North America and Europe, targeting collaborations with additional pharmaceutical and biotech firms by the end of 2026.

1. Seed

   Aug 5, 2025

   Amount

   Undisclosed

   Investors

   Locked